Raymond James analyst Chris Meekins evaluated the proposed U.S. Treasury rule and stated that intellectual property licensing deals between U.S. pharmaceutical companies and Chinese biotechs will likely remain permissible

The complex and evolving relationship between the United States and China, encompassing diplomatic, military, economic, and technological dimensions, including tensions over Taiwan, competition in the Indo-Pacific, AI development, and broader questions of global power and deterrence.